EXCLUSIVE ONLINE CONTENT
Codiak BioSciences, Inc. recently announced new preclinical data on the company’s engEx-AAV discovery program, a novel strategy that aims to leverage exosomes to improve adeno-associated virus (AAV) vector gene….
Update on Positive Pre-Clinical Results From AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease
Aeterna Zentaris Inc. recently provided an update on the positive results from pre-clinical studies of Aeterna’s Autoimmunity Modifying Biologicals (AIM Biologicals), for the potential treatment of Parkinson’s Disease (PD)…..
Artax Biopharma Closes Financing to Advance Clinical-Stage, First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases
Artax Biopharma, Inc. recently announced the close of a $26-million financing round to develop AX-158, the company’s first oral small molecule immunomodulating agent…..
Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients With Advanced Solid Tumors
Immatics N.V. recently announced the initiation of a Phase 1 clinical trial with its T cell engaging receptor (TCER) IMA401 for patients with recurrent and/or refractory….
AUM Biosciences Enters Collaboration With Roche for Clinical Development of AUM001 in Combination With Anti-PD-L1 Therapy in Solid Tumor Indications
AUM Biosciences recently announced it has entered into a clinical trial collaboration and supply agreement with Roche to evaluate AUM001, the company’s novel, highly selective….
MARKET NEWS & TRENDS
As the advantages of transdermal drug delivery grow, the global market for transdermal patches also is growing. Join DuPont™ Liveo™ Healthcare Solutions and Gattefossé Pharmaceuticals for a complimentary one-hour webinar to explore the current….
Antibody Drug Conjugates (ADCs) have a highly specific mechanism of action which is an advantage for the treatment of several oncology indications…..
Celanese and ThermoFisher Scientific have partnered together to present the value of the VitalDose® EVA drug delivery platform and manufacturing through Hot Melt Extrusion (HME) on September 9, 2021.
The Rule of 5 suggests that, for oral bioavailability, a better chance for oral absorption is obtained when the molecules are within the parameters of the Rule of 5’. However, the pharmaceutical industry is achieving oral efficacy with drugs that exceed….
Bespak by Recipharm Webinar: Learn How To Overcome Viscous Formulation Challenges For Parenteral Delivery
There have been many challenges holding back widespread adoption of self-administered injectable formulations. One of the most pressing is the need to develop an auto-injector with a fine enough needle for….
Read about how achieving good in vivo performance is a key attribute for ensuring safety and efficacy of oral solid dosage (OSD) forms intended for systemic delivery.
WHITE PAPER – Making Sub-Visible Particles Visible: Innovative Analytical Techniques for Detection & Identification
The demand for complex, often life-saving drug substances such as monoclonal antibodies, interferons, and peptides is on the rise, creating a greater need for innovative delivery mechanisms to administer these new therapeutics. For a variety of reasons, sub-visible particles….
This white paper will introduce the concept of dissolution and discuss how poloxamers are a simple yet powerful formulation approach that can enhance dissolution rate, while minimizing resource requirements.
Particle Works’ leading microfluidic technology offers a unique automated nanoparticle generation platform for the production of homogeneous, controllable, and reproducible LNPs….
Are you prepared for the HFA phasedown? With many industries switching to more environmentally friendly propellants, pMDI developers need to be ready. Recipharm explore alternative…